CycloPE®

About Path Ex

Path Ex is pioneering a direct, device-based approach to treating sepsis by physically removing pathogens from the blood. Its CycloPE® device is designed for rapid, broad-spectrum bacterial clearance and integrates with existing ICU systems. Founded in 2017 and now based in San Francisco, the company has secured non-dilutive grant funding, completed early clinical studies, and holds FDA Breakthrough Device status as it progresses toward pivotal trials and potential commercialization. The technology addresses a critical unmet need in a high-mortality condition where current antibiotic therapies are increasingly challenged by resistance.

Therapeutic Areas

Other Sepsis / Septic Shock Drugs